67 results about "Coagulation Disorder" patented technology

Progesterone antagonists and SPRM are useful to prepare a medication for the treatment or the prophylaxis of excessive uterine bleeding in women with spontaneous or iatrogenic coagulation disorders such as thrombopenia, coagulation factor deficiency or anti-coagulant therapy. Treatment will last from 1 day to 180 days.

The present invention relates to compounds to inhibit blood coagulation, and more particularly to novel diketopiperazine derivatives, pharmaceutically acceptable salts and compositions thereof, to specifically inhibit thrombin. The compound has the following general structure wherein R1, R2 and R4 consist of a hydrogen, alkyl or aryl moiety, R3 consist of an alkyl or aryl moiety, wherein R5 consists of a hydrogen, alkyl, aryl, hydroaryl, heteroaryl, hydroheteroaryl, sulfonylalkyl, sulfonylaryl, sulfonylhydroaryl, sulfonylheteroaryl or sulfonylhydroheteroaryl moiety, and wherein R6 consists of a hydrogen, alkyl, aryl, hydroaryl, heteroaryl or hydroheteroaryl moiety. Also disclosed are methods of using the compound for treating coagulation disorders such as thrombosis and heparin associated thrombocytopenia.

Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose- related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.

Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

Provided are pro-coagulant compounds (e.g., pro-coagulant peptides or peptide derivatives) and methods of using and making those compounds. Further provided are conjugates between a pro-coagulant compound of the present disclosure (e.g., pro-coagulant peptide or peptide derivative) and a polypeptide selected from FIX, FVIIa, FVIII, and platelet targeting moieties (e.g., PDG-13), wherein the compound is linked to the polypeptide optionally via a linker. The compounds and conjugates are useful for the treatment of coagulation disorders, such as hemophilia A and hemophilia B. Further provided are methods of using and making the conjugates.

Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.

Red blood cell membrane derived microparticles (RMP) are safe, economical, effective hemostatic agents in the treatment of a wide range of bleeding conditions and can be considered as universal hemostatic agents. RMP are produced from red blood cells using a high-pressure extrusion membrane shear process and can be lyophilized after production and retain activity even when stored at room temperature. RMP can be administered to original donors (autologous treatment), thus avoiding transfusion complications, or can be administered to blood type compatible recipients. RMP produced from type O, Rh negative red cells can be given to any person regardless of blood type. RMP can be administered to reduce excessive bleeding resulting from trauma, surgeries, invasive procedures and various bleeding disorders such as platelet disorders, either congenital or acquired, and coagulation disorders, either congenital or acquired.

The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including (a) a binding element capable of targeting an activated platelet and (b) a label. Applicant has shown that agents and probes directed to activated platelets are useful in the diagnosis and therapy of coagulation disorders.

DNA isolates coding for tissue factor protein and methods of obtaining such DNA and producing tissue factor protein using recombinant expression systems for use in therapeutic composition for the treatment of coagulation disorders.

The present invention related to a method and therapeutic composition for the treatment of coagulation disorders comprising administration of a lipoprotein associated coagulation inhibitor.

Progesterone antagonists and SPRM are useful to prepare a medication for the treatment or the prophylaxis of excessive uterine bleeding in women with spontaneous or iatrogenic coagulation disorders such as thrombopenia, coagulation factor deficiency or anti-coagulant therapy. Treatment will last from 1 day to 180 days.

Red blood cell membrane derived microparticles (RMP) are safe, economical, effective hemostatic agents in the treatment of a wide range of bleeding conditions and can, therefore, be considered as universal hemostatic agents. Effective RMP are produced from red blood cells using a high-pressure extrusion membrane shear process. The RMP can be lyophilized after production and retain activity even when stored at room temperature. RMP can be administered to original donors (autologous treatment), thus avoiding transfusion complications, or can be administered to blood type compatible recipients. RMP produced from type O, Rh negative red cells can be given to any person regardless of blood type. RMP can be administered to reduce excessive bleeding resulting from trauma, surgeries, invasive procedures and various bleeding disorders such as platelet disorders, either congenital or acquired, and coagulation disorders, either congenital or acquired. Administration of RMP prepared according to the invention demonstrates effectiveness in safely reducing bleeding.

Methods for the treatment of coagulation disorders using Factor V / Va variants are provided.

The subject invention provides anticoagulant compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R3, n and Ar are as defined herein. The compounds of the subject invention can be used to treat at-risk populations thereby bringing relief of symptoms, improving the quality of life, preventing acute and long-term complications, reducing mortality and treating accompanying disorders. The invention further comprises pharmaceutical compositions comprising the compounds and salts of the invention, as well as methods of using the compounds, salts, and compositions of the invention.

The subject invention provides anticoagulant compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R3, n and Ar are as defined herein. The compounds of the subject invention can be used to treat at-risk populations thereby bringing relief of symptoms, improving the quality of life, preventing acute and long-term complications, reducing mortality and treating accompanying disorders. The invention further comprises pharmaceutical compositions comprising the compounds and salts of the invention, as well as methods of using the compounds, salts, and compositions of the invention.

This invention is drawn to compounds which are more easily metabolized by the metabolic drug detoxification systems. Particularly, warfarin analogs which have been designed to include esters within the structure of the compounds are taught. The invention teaches methods of reducing the toxicity of drugs comprising the introduction of ester groups into drugs during the synthesis of the drug. This invention is also drawn to methods of treating coagulation disorders comprising the administration of compounds which have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester containing warfarin, analogs are also taught.

The invention relates to a method for preparing liquid fibrinogen (FIB) detection solution. The solution is mainly used for monitoring the disturbance of blood coagulation, the hemorrhagic disease, the disseminated intravascular coagulation (DIC), the diabetes, the acidosis, the atherosclerosis and other disease symptoms. Along with the wide clinical application of thrombus and hemostasis detection, the fibrinogen (FIB) detection is the routine detection item of the thrombus and hemostasis detection, and has important clinical diagnosis value. The method adopts cow thrombin as a main raw material, and uses the Von clauss method (NCCLS recommended) to prepare the novel liquid fibrinogen (FIB) detection solution. The novel stable system solves the difficulty of maintaining the stability of the solution in the liquid state, and the method has the advantages of high sensitivity, convenient use, low experimental error, high stability, favorable compatibility, low cost, and the like.

The subject invention provides anticoagulant compounds of formula I:and pharmaceutically acceptable salts thereof, wherein R1, R3, n and Ar are as defined herein. The compounds of the subject invention can be used to treat at-risk populations thereby bringing relief of symptoms, improving the quality of life, preventing acute and long-term complications, reducing mortality and treating accompanying disorders. The invention further comprises pharmaceutical compositions comprising the compounds and salts of the invention, as well as methods of using the compounds, salts, and compositions of the invention.

The present invention concerns methods for determining platelet medicated clot formation. Specifically, the invention provides a method for determining platelet-medicated clot formation in a blood sample comprising: (i) obtaining sample of blood, and optionally mixing same with an anti-coagulant in an amount effective to inhibit clot formation; (ii) in a vessel, mixing the sample with a minute amount of an initiator to obtain a mixed sample, the amount being effective to initiate coagulation; (iii) rotating the mixed sample inside the vessel, whereby shear forces are developed at the surface of said vessel in a manner and for a time sufficient to allow adhesion of platelets at the surface of said vessel; (iv) determining clot formation at the surface of said adherent platelets. The method has different applications, among others, for determining a coagulation disorder in a subject having a coagulation factor dysfunction.

The invention discloses an emergency assisted hemostasis device for a patient having coagulation disorders. The emergency assisted hemostasis device comprises a main body, wherein a first bandage and a second bandage are arranged on the surfaces of two sides of the main body; a magic tape male side is arranged on the side surface of the first bandage, and a magic tape female side, which corresponds to the magic tape male side, is arranged on the side surface of the second bandage; a hemostasis medicine cavity is formed in the main body; a dosing opening is formed in the upper surface of the main body, and a PLC controller is arranged on the side surface of the main body; and an input end of the PLC controller is electrically connected to an output end of an internal battery. With the application of the emergency assisted hemostasis device for the patient having coagulation disorders, a wound of the patient can undergo emergency hemostasis in the case of emergency, so that more serious hurt to the patient due to excessive bleeding is prevented, and the device is conducive to body health of the patient; the main body and an affected limb of the patient are fixed by virtue of the first bandage and the second bandage; the first bandage is longer than the second bandage, and elasticity of the bandages is adjustable; and in addition, an effect of compression hemostasis can be achieved.

The invention discloses a method for detecting hemostatic capability. The method comprises: preparing anticoagulant blood from venous blood and anticoagulant with 0.13mol / L of sodium citrate in a volume ratio of 9:1; centrifuging an anticoagulant blood sample for 15 minutes at a speed of 3,000 r / min and sucking plasma to be detected; performing OHP determination of overall hemostatic capability, OCP determination of overall blood coagulation capability and OFP judgment of overall fibrinolytic capability; indicating the existence of blood coagulation disturbance when OCP and OHP are less than the lower limit of normal reference values; indicating the existence of hypercoagulable state when the OCP and the OHP are greater than the upper limit of the normal reference values; and indicating the reduction of fibrinolytic function when OFP value is less than 41.61 percent. The method has the advantages of good stability and repeatability, easy operation and low cost, and is worthy of popularization.

The invention discloses a sliding hemostatic needle which comprises an automatic locking device, an automatic flick device, an unlocking button, hemostatic needle bodies, a push rod and a shell, wherein all the components are arranged in the shell. A clamping sheet is arranged on the shell. The clamping sheet can freely fall onto clamping teeth of the push rod under the action of a small-sized magnet to fix the hemostatic needle bodies, the clamp sheet falling onto the clamp teeth is lifted when the unlocking button is pressed so that a locking state can be removed, and the hemostatic needle bodies return to an original position through the automatic flick device arranged at one end of the shell. The sliding hemostatic needle has the advantages of being simple in structure, convenient to carry and flexible in use; the hemostatic effect is achieved in a manner that a bleeding part is clamped by the hemostatic needle bodies, and the sliding hemostatic needle has the obvious hemostatic effect on patients suffering from vascular injury hemorrhage and patients suffering from coagulation disorders.